early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy早期反应intravitreal之初在典型的新生血管性年龄相关性黄斑变性和polypoidal脉络膜血管病变.pdfVIP

Hindawi Publishing Corporation Journal of Ophthalmology Volume 2011, Article ID 742020, 6 pages doi:10.1155/2011/742020 Clinical Study Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Wataru Matsumiya, Shigeru Honda, Hiroaki Bessho, Sentaro Kusuhara, Yasutomo Tsukahara, and Akira Negi Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan Correspondence should be addressed to Shigeru Honda, sighonda@med.kobe-u.ac.jp Received 25 January 2011; Revised 12 April 2011; Accepted 14 April 2011 Academic Editor: Rupert M. Menapace Copyright © 2011 Wataru Matsumiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. To evaluate the early response to intravitreal ranibizumab (IVR) in two different phenotypes of age-related macular degenerations (AMD): typical neovascular AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Methods. Sixty eyes from 60 patients (tAMD 28, PCV 32 eyes) were recruited. Three consecutive IVR treatments (0.5 mg) were performed every month. Change in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) was then compared between the tAMD and PCV groups. Results. The mean BCVA logMAR was significantly improved at month 1 and month 3 after the initial IVR in the tAMD group, but there was no change in the PCV group. Both phenotypes showed significant improvements in the CRT during the 3 months after the initial IVR. There were no significant differences in the improvements of the CRT in the tAMD versus the P